Difference between revisions of "Team:BostonU/HP/Gold Integrated"

Line 233: Line 233:
 
   <p class="body-type mainwrap">Dr. Zaman covered two major topics in our discussion with him: accessibility and robustness. When addressing accessibility, he indicated that our device should be able to be used successfully by local health personnel. When designing new technologies, it is important that they fit easily into existing healthcare structure so that they can be adapted with ease. With regards to robustness, Dr. Zaman brought up a number of technical difficulties our technology might encounter if utilized outside of the lab. One issue when attempting to detect RNAs is that RNase enzymes, which are ubiquitous in the environment [1], are highly likely to contaminate RNA samples when not used in a sterile area. Due to the scarcity of sterile facilities needed to mitigate this issue in low-resource areas, RNAse contamination would be highly likely and thus render our device unusable. Dr. Zaman was unconvinced that our project, in its proposed form, would see success when used in the contexts that we were considering.</p>
 
   <p class="body-type mainwrap">Dr. Zaman covered two major topics in our discussion with him: accessibility and robustness. When addressing accessibility, he indicated that our device should be able to be used successfully by local health personnel. When designing new technologies, it is important that they fit easily into existing healthcare structure so that they can be adapted with ease. With regards to robustness, Dr. Zaman brought up a number of technical difficulties our technology might encounter if utilized outside of the lab. One issue when attempting to detect RNAs is that RNase enzymes, which are ubiquitous in the environment [1], are highly likely to contaminate RNA samples when not used in a sterile area. Due to the scarcity of sterile facilities needed to mitigate this issue in low-resource areas, RNAse contamination would be highly likely and thus render our device unusable. Dr. Zaman was unconvinced that our project, in its proposed form, would see success when used in the contexts that we were considering.</p>
 
   <p class="body-type mainwrap">&nbsp;</p>
 
   <p class="body-type mainwrap">&nbsp;</p>
   <p class="body-type mainwrap">We then visited the Fraunhofer Center for Manufacturing Innovation’s Boston facility to discuss microfluidic systems and their applications. We learned that microfluidics can significantly increase efficiency of synthetic biologists’ work, since they can enable experiments to run semi-autonomously once all reagents are added. This automation allows scientists to take the time to work on other aspects of their projects such as data analysis and experimental design. Microfluidic chips are also portable and easy to use, which make them more accessible for point-of-care applications. These characteristics of microfluidics aligned with our initial intention of developing user-friendly diagnostic devices. However, through further conversations with Fraunhofer and our collaboration experience with <a href="https://2017.igem.org/Team:BostonU/Collaborations">BostonU Hardware,</a>we realized that with our resources and protocol, encapsulating our system in a microfluidic device is not possible with the current state of our toehold technology. </p>
+
   <p class="body-type mainwrap">We then visited the Fraunhofer Center for Manufacturing Innovation’s Boston facility to discuss microfluidic systems and their applications. We learned that microfluidics can significantly increase efficiency of synthetic biologists’ work, since they can enable experiments to run semi-autonomously once all reagents are added. This automation allows scientists to take the time to work on other aspects of their projects such as data analysis and experimental design. Microfluidic chips are also portable and easy to use, which make them more accessible for point-of-care applications. These characteristics of microfluidics aligned with our initial intention of developing user-friendly diagnostic devices. However, through further conversations with Fraunhofer and our collaboration experience with <a href="https://2017.igem.org/Team:BostonU/Collaborations">BostonU Hardware,</a> we realized that with our resources and protocol, encapsulating our system in a microfluidic device would not be possible given the current state of our toehold technology. </p>
 
   <p class="body-type mainwrap">&nbsp;</p>
 
   <p class="body-type mainwrap">&nbsp;</p>
 
   <p class="body-type mainwrap">Our conversations with Dr. Zaman and with the Fraunhofer team thus steered our primary focus toward making our project a foundational advance of the toehold technology in our own cell-free system. Future conversations within our team led to the incorporation of recombinases and the shift to a molecular computation focus for our project. We still see potential applications in microfluidic devices, but within the scope of our project we instead wanted to focus on developing this new molecular computational technology in a standalone system.</p>
 
   <p class="body-type mainwrap">Our conversations with Dr. Zaman and with the Fraunhofer team thus steered our primary focus toward making our project a foundational advance of the toehold technology in our own cell-free system. Future conversations within our team led to the incorporation of recombinases and the shift to a molecular computation focus for our project. We still see potential applications in microfluidic devices, but within the scope of our project we instead wanted to focus on developing this new molecular computational technology in a standalone system.</p>

Revision as of 03:04, 31 October 2017

INTEGRATED HUMAN PRACTICES